© 2005 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD)

(art)n Artists: 

Ellen Sandor, Nick Gaul and Janine Fron

Collaborative Artists: 

Frank Axe and Hui Cai, J&JPRD

Mike Randal, Sunesis Pharmaceuticals

Size: 
30x40
Medium: 

PHSCologram

Materials: 

Duratrans, Kodalith, Plexiglas

Exhibitions: 

none

Collections: 

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD)

Literature: 

none

Description: 

Inappropriate response of the immune system to various antigens leads to diseases ranging from rheumatoid arthritis, multiple sclerosis and lupus, to atopic allergies such as hay fever, asthma, atopic dermatitis and food allergies. The goal of immunotherapy is to minimize allergen activation of the immune system or to disrupt the allergic response.



At the center of this image is a non-covalent inhibitor (blue molecule) in a binding pocket of a cysteine protease that modulates antigen presentation to T-cells. Drugs that inhibit proteolytic activity in this manner might curb the allergic response. X-ray crystallography, molecular modeling, NMR spectroscopy and gel electrophoresis are enabling technologies used to probe this enzyme-inhibitor complex.



PHSCologram: rotated, computer-interleaved Duratrans® transparency and film, and Kodalith® film mounted on Plexiglas®.



© 2005 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD)